Apellis Pharmaceuticals Inc, Aerie Pharmaceuticals, Aldeyra Therapeutics, and ProQR Therapeutic at Citi BioPharma Conference (Virtual) - Panel Transcript
Okay. Great. I think we have everyone in the live session. So again, to the second panel that I'm moderating for the day, this is entitled Ophthalmology - Seeing 20/20 in 2020. I'm Yigal Nochomovitz. If you're interested in asking questions, you can either just e-mail me directly, [email protected], or there's a feature on the showcase virtual app where you can submit a question via chat. So just feel free to do that.
So it's my pleasure to have with me this morning 4 distinguished guests, all CEOs of their respective companies: from Aerie, Vince Anido; from Aldeyra, Todd Brady; from Apellis, Cedric Francois; and last but not least, from ProQR, Daniel de Boer. So welcome, all gentlemen. Thank you very much for taking the time to chat with us today.
Questions & Answers
I think what I'll do is just as a -- just very preliminarily, if each of you could give a very brief 1- to 2-minute overview of each
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |